Saphenous vein graft (SVG) closure after coronary artery bypass grafting (CABG) is an underreported and poorly understood problem. Imperfect surgical technique is frequently blamed but this can be detected using flow measurement technology, allowing us to focus on other causal factors. We have developed clinical tools to show that endothelial cell (EC) disruption in the saphenous vein graft (SVG) and aspirin resistance (ASA-R) after CABG are significant predictors of graft failure. Analysis of coronary sinus (CS) blood samples obtained from these patients revealed that the level of F1.2, a marker of thrombin formation, relates to ASA- R and abnormalities of blood flow and EC integrity in the SVG (i.e. Virchow's triad). On the basis of this and other observations, we hypothesize that a dysregulated burst of thrombin within the SVG is a common pathway in the development of graft failure. This hypothesis will be tested first with an animal model in order to establish that controlled manipulations in SVG thrombogenecity and the other components of Virchow's triad have a consistent and measurable impact of thrombin within the SVG. We have developed a comprehensive strategy for analyzing the role of thrombin in our porcine CABG model by monitoring its stimulus (tissue factor), formation (F1.2 peptide release), deposition (activity assessed directly on the SVG lumen), effects (imaging of mural thrombus and analysis of platelet derived microparticles) and inhibition (TAT complex). Novel approaches to prevent thrombin production within the high risk SVG will be tested. Because it is difficult to model ASA-R and other common clinical risk factors for SVG thrombosis in animals, a sufficiently powered clinical trial will be required to establish the link between a burst in thrombin production within the SVG and early graft failure. Lay Description: Familiarity, concerns about the safety of alternatives, and acceptable intermediate-term results have led to established practice patterns such as use of aspirin as the sole antiplatelet agent and routine use of the SVG as a conduit for most bypass cases. Definitive alterations in management strategies after CABG await a clear understanding of why grafts fail and the elucidation of treatable risk factors, e.g. regional thrombin dysregulation. Because anticoagulation is not harmless in these patients, reliable identification of the risk of SVG failure would provide a rationale basis to selectively intervene and optimize graft patency without increasing bleeding in the population as a whole.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
7R01HL084080-03
Application #
7576107
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Hasan, Ahmed AK
Project Start
2007-02-01
Project End
2012-01-31
Budget Start
2009-02-01
Budget End
2010-01-31
Support Year
3
Fiscal Year
2009
Total Cost
$363,215
Indirect Cost
Name
Boston Medical Center
Department
Type
DUNS #
005492160
City
Boston
State
MA
Country
United States
Zip Code
02118
Kiani, Soroosh; Kurian, Dinesh; Henkin, Stanislav et al. (2016) Direct to consumer advertising of robotic heart bypass surgery: effectiveness, patient satisfaction and clinical outcomes. Int J Pharm Healthc Mark 10:358-375
Howk, Kreg; Fortier, Jason; Poston, Robert (2016) A Novel Hemostatic Patch That Stops Bleeding in Cardiovascular and Peripheral Vascular Procedures. Ann Vasc Surg 31:186-95
Chiang, Cheng-Hsien; Yeh, Ming-Long; Chen, Wei-Ling et al. (2016) Apparatus for Comparison of Pullout Forces for Various Thoracic Stent Grafts at Varying Neck Angulations and Oversizes. Ann Vasc Surg 31:196-204
Khalpey, Zain; Korovin, Lev; Chitwood Jr, W Randolph et al. (2014) Robot-assisted septal myectomy for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg 147:1708-9
Khalpey, Zain; Sydow, Nicole; Slepian, Marvin J et al. (2014) How to do it: thoracoscopic left ventricular assist device implantation using robot assistance. J Thorac Cardiovasc Surg 147:1423-5
Vainrub, Sophia; Patanwala, Asad E; Cosgrove, Richard et al. (2014) Bleeding outcomes in patients given clopidogrel within 5 days of robotic coronary artery bypass graft procedure. Ann Pharmacother 48:48-53
Khalpey, Zain; Sydow, Nicole; Paidy, Samata et al. (2014) Robotic-assisted implantation of ventricular assist device after sternectomy and pectoralis muscle flap. ASAIO J 60:742-3
Goodnough, Lawrence T; Smith, Peter K; Levy, Jerrold H et al. (2013) Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis. J Thorac Cardiovasc Surg 145:1077-1082.e4
Kiani, Soroosh; Brown, Alex K; Kurian, Dinesh J et al. (2012) Risk of renal dysfunction after less invasive multivessel coronary artery bypass grafting. Innovations (Phila) 7:180-6
Kiani, Soroosh; Desai, Pranjal H; Thirumvalavan, Nannan et al. (2012) Endoscopic venous harvesting by inexperienced operators compromises venous graft remodeling. Ann Thorac Surg 93:11-7; discussion 17-8

Showing the most recent 10 out of 33 publications